Blade Air Mobility 2025 Q2 Earnings Narrowed Losses with 67% Improvement

Blade Air Mobility (BLDE) reported fiscal 2025 Q2 earnings on August 6, 2025, with narrowed losses and revenue growth. The company exceeded expectations with its significant reduction in net loss and maintained full-year guidance, though long-term profitability remains elusive.

Revenue
Blade Air Mobility reported total revenue of $70.80 million for 2025 Q2, a 4.2% increase from $67.94 million in the same period last year. The Short Distance segment generated $17.20 million, while the Jet and Other segment contributed $8.50 million. The Medical division, specifically the MediMobility Organ Transport business, was the largest contributor with $45.11 million in revenue, highlighting its growing importance to the company’s overall performance.

Earnings/Net Income
Blade Air Mobility narrowed its losses, reporting a net loss of $3.74 million in 2025 Q2, down 67.0% from $11.33 million in the prior-year quarter. On a per-share basis, the company posted a loss of $0.05, a 66.7% improvement from $0.15 in 2024 Q2. Despite this progress, the company remains unprofitable, with sustained losses for five consecutive years in the same period.

Price Action
Blade Air Mobility’s stock edged up 0.73% during the latest trading day, gained 5.58% over the past week, but declined 0.48% month-to-date.

Post-Earnings Price Action Review
Following the earnings report, a strategy of buying BLDE shares after a revenue increase and holding for 30 days delivered a disappointing -12.82% return, significantly underperforming the 48.58% benchmark return. The strategy recorded an excess return of -61.40%, a CAGR of -4.63%, and a Sharpe ratio of -0.07, indicating a high-risk investment with negative returns relative to the risk-free rate.

CEO Commentary
Robert S. Wiesenthal, CEO, highlighted the strategic divestiture of the Blade Passenger business to Joby Aviation for up to $125 million. This move positions the Medical segment as an independent public company, Strata Critical Medical. Wiesenthal emphasized the Medical division’s growth from 12% to 60% of revenue since 2020 and its contribution to 85% of adjusted EBITDA. He expressed optimism about the company’s future, noting strong organic growth, disciplined capital allocation, and a $200 million cash balance post-transaction.

Guidance
Blade reaffirmed its full-year 2025 revenue guidance of $245–$265 million and double-digit adjusted EBITDA. The company expects the sale of the Blade Passenger business to be neutral to adjusted EBITDA and free cash flow moving forward. For the Medical segment, management anticipates mid-teens revenue growth in the second half of 2025, with adjusted EBITDA margins improving to approximately 15%.

Additional News
On August 5, 2025, Joby Aviation (JOBY) announced an agreement to acquire Blade Air Mobility’s U.S. and European passenger business, including lounges, terminals, and the Blade brand, for up to $125 million in stock or cash. The transaction, expected to close within weeks, caused Blade’s shares to surge nearly 29% pre-market. The Medical division, which will operate independently as Strata Critical Medical, will retain its public listing and continue a long-term partnership with Joby. Joby will also serve as the preferred eVTOL partner for Blade’s organ transport business. Joby’s CEO, JoeBen Bevirt, called the acquisition strategic, supporting the company’s expansion and leadership in the eVTOL market.